Drug Patents Expiring in 2027

1. List of Abilify drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(4 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of ABILIFY before it's patent expiration?
More Information on Dosage

2. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(4 years from now)

US9444503 OTSUKA Active signal processing personal health signal receivers
Nov, 2027

(4 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Adjunctive treatment of major depressive disorder (mdd); Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Abraxane drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8034375

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Dec 6, 2022
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's patent expiration?
More Information on Dosage

4. List of Actoplus Met drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101660 TAKEDA PHARMS USA Solid preparation
Jan, 2027

(3 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2005

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

5. List of Acular Ls drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8008338

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2027

(4 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating or preventing ocular pain in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's patent expiration?
More Information on Dosage

6. List of Adrenaclick drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7905352 IMPAX Kits containing medicine injection devices and containers
Apr, 2027

(4 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

7. List of Advil Allergy Sinus drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287 GLAXOSMITHKLINE Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
Feb, 2027

(4 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

8. List of Alsuma drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7811254 MERIDIAN MEDCL Autoinjector with needle depth adapter
Aug, 2027

(4 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 29 June, 2010

Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

9. List of Altabax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7875630 ALMIRALL Process salts compositions and use
Feb, 2027

(4 years from now)

Drugs and Companies using RETAPAMULIN ingredient

Market Authorisation Date: 12 April, 2007

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage

10. List of Amitiza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8779187 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(3 years from now)

US8338639 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(3 years from now)

US8026393 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Oct, 2027

(4 years from now)

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of AMITIZA before it's patent expiration?
More Information on Dosage

11. List of Amyvid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7687052 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(4 years from now)

US8506929 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(4 years from now)

Drugs and Companies using FLORBETAPIR F-18 ingredient

Market Authorisation Date: 06 April, 2012

Treatment: Amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

12. List of Anoro Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304 GLAXOSMITHKLINE Medicament dispenser
Jun, 2027

(4 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage

13. List of Antizol drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553863 PAR PHARM INC Ultrapure 4-methylpyrazole
Jun, 2027

(4 years from now)

Drugs and Companies using FOMEPIZOLE ingredient

Market Authorisation Date: 04 December, 1997

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of ANTIZOL before it's patent expiration?
More Information on Dosage

14. List of Argatroban In Sodium Chloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7589106 EAGLE PHARMS Alcohol free formulation of argatroban
Sep, 2027

(4 years from now)

US7687516 EAGLE PHARMS Alcohol free formulation of argatroban
Sep, 2027

(4 years from now)

Drugs and Companies using ARGATROBAN ingredient

Market Authorisation Date: 29 June, 2011

Treatment: Method of treating thrombosis; Method of treating an argatroban treatable condition

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ARGATROBAN IN SODIUM CHLORIDE before it's patent expiration?
More Information on Dosage

15. List of Arnuity Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 20 August, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

16. List of Aubagio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410

(Pediatric)

SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Mar, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's patent expiration?
More Information on Dosage

17. List of Auvi-q drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system
Feb, 2027

(4 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2027

(4 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery
May, 2027

(4 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

18. List of Aveed drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Mar, 2027

(4 years from now)

US8338395 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
May, 2027

(4 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).

Dosage: INJECTABLE;INTRAMUSCULAR

How can I launch a generic of AVEED before it's patent expiration?
More Information on Dosage

19. List of Axiron drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8807861 ELI LILLY AND CO Spreading implement
Feb, 2027

(4 years from now)

US8419307 ELI LILLY AND CO Spreading implement
Feb, 2027

(4 years from now)

US9289586 ELI LILLY AND CO Spreading implement
Feb, 2027

(4 years from now)

US8435944 ELI LILLY AND CO Method and composition for transdermal drug delivery
Sep, 2027

(4 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 23 November, 2010

Treatment: A method of transdermal administration of a physiologically active agent to a subject.; A method of increasing the testosterone blood level of a person in need thereof; A method of increasing the testosterone blood level of an adult male subject in need thereof

Dosage: SOLUTION, METERED;TRANSDERMAL

How can I launch a generic of AXIRON before it's patent expiration?
More Information on Dosage

20. List of Azilect drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7815942 TEVA Rasagiline formulations of improved content uniformity
Aug, 2027

(4 years from now)

Drugs and Companies using RASAGILINE MESYLATE ingredient

Market Authorisation Date: 16 May, 2006

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

More Information on Dosage

21. List of Balcoltra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7838042 AVION PHARMS Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions
Jun, 2027

(4 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 09 January, 2018

Treatment: Administration of ferrous bisglycinate tablets

Dosage: TABLET;ORAL

How can I launch a generic of BALCOLTRA before it's patent expiration?
More Information on Dosage

22. List of Belbuca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Treatement of pain by transmucosal delivery of buprenorphine

Dosage: FILM;BUCCAL

How can I launch a generic of BELBUCA before it's patent expiration?
More Information on Dosage

23. List of Beleodaq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH Pharmaceutical formulations of HDAC inhibitors
Oct, 2027

(4 years from now)

Drugs and Companies using BELINOSTAT ingredient

Market Authorisation Date: 03 July, 2014

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of BELEODAQ before it's patent expiration?
More Information on Dosage

24. List of Breo Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304 GLAXO GRP LTD Medicament dispenser
Jun, 2027

(4 years from now)

US9333310 GLAXO GRP LTD Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXO GRP LTD Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations

Dosage: POWDER;INHALATION

More Information on Dosage

25. List of Bunavail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's patent expiration?
More Information on Dosage

26. List of Bydureon drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(4 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(4 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(4 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8758292 ASTRAZENECA AB Administering apparatus with functional drive element
Nov, 2027

(4 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
M Feb 15, 2022
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

27. List of Bydureon Bcise drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(4 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(4 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(4 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
M Feb 15, 2022
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

28. List of Byfavo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US10961250 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 6, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

29. List of Byvalson drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838552 ALLERGAN Compositions comprising nebivolol
Oct, 2027

(4 years from now)

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Market Authorisation Date: 03 June, 2016

Treatment: Method of treating hypertension

Dosage: TABLET;ORAL

How can I launch a generic of BYVALSON before it's patent expiration?
More Information on Dosage

30. List of Cabenuva Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

31. List of Camcevi Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744207 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(3 years from now)

US10646572 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(3 years from now)

US9572857 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(3 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 25, 2024

Drugs and Companies using LEUPROLIDE MESYLATE ingredient

Market Authorisation Date: 25 May, 2021

Treatment: NA

Dosage: EMULSION;SUBCUTANEOUS

More Information on Dosage

32. List of Cardene drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(4 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(4 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(4 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE before it's patent expiration?
More Information on Dosage

33. List of Chloraprep One-step drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7422388 BECTON DICKINSON CO Applicator for coloring antiseptic
Apr, 2027

(4 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 14 July, 2000

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SPONGE;TOPICAL

More Information on Dosage

34. List of Chlorhexidine Gluconate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7935093 SAGE PRODS Disinfectant delivery system and method of providing alcohol-free disinfection
Oct, 2027

(4 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH;TOPICAL

More Information on Dosage

35. List of Colazal drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7452872

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(4 years from now)

US7625884

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(4 years from now)

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 18 July, 2000

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of COLAZAL before it's patent expiration?
More Information on Dosage

36. List of Combivent Respimat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(4 years from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

37. List of Contrave drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107837 NALPROPION Sustained release formulation of naltrexone
Jun, 2027

(4 years from now)

US9125868 NALPROPION Methods for administering weight loss medications
Nov, 2027

(4 years from now)

US10307376 NALPROPION Methods for administering weight loss medications
Nov, 2027

(4 years from now)

US8722085 NALPROPION Methods for administering weight loss medications
Nov, 2027

(4 years from now)

US8318788 NALPROPION Layered pharmaceutical formulations
Nov, 2027

(4 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion based on an escalating dose schedule; Use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

38. List of Corlanor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7867996

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Jun, 2027

(4 years from now)

Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 April, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of CORLANOR before it's patent expiration?
More Information on Dosage

39. List of Cotellic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8362002

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Apr, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 10, 2022
New Indication (I) Oct 28, 2025
M Jul 28, 2025
Pediatric Exclusivity (PED) Jan 28, 2026

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Market Authorisation Date: 10 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

40. List of Cresemba drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Sep, 2027

(4 years from now)

US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2020
Orphan Drug Exclusivity (ODE) Mar 6, 2022
Generating Antibiotic Incentives Now (GAIN) Mar 6, 2027

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: March, 2026

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

41. List of Daklinza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9421192 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

US8642025 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900566 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; Method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL

More Information on Dosage

42. List of Dexilant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Feb, 2027

(4 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Mar, 2027

(4 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's patent expiration?
More Information on Dosage

43. List of Dificid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378508 CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jul, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7906489 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Mar, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

US8859510 CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

US7906489

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jan 24, 2023
Orphan Drug Exclusivity (ODE) Jan 24, 2027
Pediatric Exclusivity (PED) Jul 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 27 May, 2011

Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older; Treatment of microbial infections

Dosage: TABLET;ORAL

How can I launch a generic of DIFICID before it's patent expiration?
More Information on Dosage

44. List of Dovato drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Apr 8, 2022
New Indication (I) Aug 6, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's patent expiration?
More Information on Dosage

45. List of Dsuvia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744129 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8252329 ACELRX PHARMS Bioadhesive drug formulations for oral transmucosal delivery
Jan, 2027

(3 years from now)

US9320710 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8226978 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8865211 ACELRX PHARMS Bioadhesive drug formulations for oral transmucosal delivery
Jan, 2027

(3 years from now)

US10245228 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US10507180 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8252328 ACELRX PHARMS Bioadhesive drug formulations for oral transmucosal delivery
Jan, 2027

(3 years from now)

US8778394 ACELRX PHARMS Small-volume oral transmucosal dosage forms
Jan, 2027

(3 years from now)

US8535714 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8778393 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(3 years from now)

US8231900 ACELRX PHARMS Small-volume oral transmucosal dosage
Jan, 2027

(3 years from now)

US10342762 ACELRX PHARMS Small-volume oral transmucosal dosage forms
Jan, 2027

(3 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

46. List of Duaklir Pressair drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8051851 ASTRAZENECA Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
Apr, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

47. List of Duavee drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7683051 WYETH PHARMS Crystalline polymorph of bazedoxifene acetate
Mar, 2027

(4 years from now)

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Market Authorisation Date: 03 October, 2013

Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage

48. List of Duetact drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700128 TAKEDA PHARMS USA Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
Jan, 2027

(4 years from now)

Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 July, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DUETACT before it's patent expiration?
More Information on Dosage

49. List of Durysta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8206737 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

50. List of Dyanavel Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086087 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8883217 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8597684 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US9675703 TRIS PHARMA INC Modified release formulations containing drug - ion exchange resin complexes
Mar, 2027

(4 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 19 October, 2015

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

51. List of Dyanavel Xr 10 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8337890 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US9675704 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 04 November, 2021

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

52. List of Dyloject drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946292 JAVELIN PHARMS INC Formulations of low dose diclofenac and beta-cyclodextrin
Mar, 2027

(4 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Management of pain

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of DYLOJECT before it's patent expiration?
More Information on Dosage

53. List of Edluar drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597281 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Apr, 2027

(4 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of EDLUAR before it's patent expiration?
More Information on Dosage

54. List of Elepsia Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163306 TRIPOINT Oral drug delivery system
Sep, 2027

(4 years from now)

US8431156 TRIPOINT Pharmaceutical composition
Oct, 2027

(4 years from now)

US8470367 TRIPOINT Oral drug delivery system
Oct, 2027

(4 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 20 December, 2018

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

55. List of Embeda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7682633 ALPHARMA PHARMS Pharmaceutical composition
Jun, 2027

(4 years from now)

US8158156 ALPHARMA PHARMS Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
Jun, 2027

(4 years from now)

US8846104 ALPHARMA PHARMS Pharmaceutical compositions for the deterrence and/or prevention of abuse
Jun, 2027

(4 years from now)

US8877247 ALPHARMA PHARMS Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
Jun, 2027

(4 years from now)

US7682634 ALPHARMA PHARMS Pharmaceutical compositions
Jun, 2027

(4 years from now)

US7815934 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Dec, 2027

(4 years from now)

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatement by orally administering an intact composition as claimed.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of EMBEDA before it's patent expiration?
More Information on Dosage

56. List of Emend drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(4 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of EMEND before it's patent expiration?
More Information on Dosage

57. List of Emend drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MERCK Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(4 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 26 March, 2003

Treatment: Prevention of postoperative nausea and vomiting; For the prevention of nausea and vomiting associated with chemotherapy

Dosage: CAPSULE;ORAL

How can I launch a generic of EMEND before it's patent expiration?
More Information on Dosage

58. List of Empaveli drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169307 APELLIS PHARMS Potent compstatin analogs
Nov, 2027

(4 years from now)

US7989589 APELLIS PHARMS Compstatin analogs with improved activity
Dec, 2027

(4 years from now)

US7888323 APELLIS PHARMS Potent compstatin analogs
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 14, 2026
Orphan Drug Exclusivity (ODE) May 14, 2028

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of complement inhibitor pegcetacoplan

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

59. List of Entresto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877938 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9388134

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(4 years from now)

US8877938

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Oct 1, 2022
M Feb 16, 2024
Pediatric Exclusivity (PED) Apr 1, 2023

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's patent expiration?
More Information on Dosage

60. List of Epiduo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8445543 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(4 years from now)

US8071644 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(4 years from now)

US8129362 GALDERMA LABS LP Combination/association of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(4 years from now)

US8080537 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(4 years from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of EPIDUO before it's patent expiration?
More Information on Dosage

61. List of Erleada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9388159 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802689 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Mar, 2027

(4 years from now)

US9987261 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 14, 2023
New Indication (I) Sep 17, 2022

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of metastatic castration-sensitive prostate cancer (mcspc)

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's patent expiration?
More Information on Dosage

62. List of Esbriet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7767700 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(4 years from now)

US8420674 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(4 years from now)

US7696236 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(4 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Market Authorisation Date: 15 October, 2014

Treatment: Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis

Dosage: CAPSULE;ORAL

How can I launch a generic of ESBRIET before it's patent expiration?
More Information on Dosage

63. List of Eucrisa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501712 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(4 years from now)

US9682092 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(4 years from now)

US8501712

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(4 years from now)

US9682092

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Mar 23, 2023
Pediatric Exclusivity (PED) Jun 14, 2022

Drugs and Companies using CRISABOROLE ingredient

Market Authorisation Date: 14 December, 2016

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

How can I launch a generic of EUCRISA before it's patent expiration?
More Information on Dosage

64. List of Evzio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system
Feb, 2027

(4 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2027

(4 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery
May, 2027

(4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

65. List of Evzio (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system
Feb, 2027

(4 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2027

(4 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery
May, 2027

(4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

66. List of Fanapt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586610 VANDA PHARMS INC Methods for the administration of iloperidone
Nov, 2027

(4 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Market Authorisation Date: 06 May, 2009

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6

Dosage: TABLET;ORAL

How can I launch a generic of FANAPT before it's patent expiration?
More Information on Dosage

67. List of Farxiga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Feb 22, 2022
New Indication (I) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's patent expiration?
More Information on Dosage

68. List of Fibricor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7741373 ATHENA Methods of use of fenofibric acid
Aug, 2027

(4 years from now)

US7569612 ATHENA Methods of use of fenofibric acid
Aug, 2027

(4 years from now)

US7915247 ATHENA Methods of use of fenofibric acid
Aug, 2027

(4 years from now)

US7741374 ATHENA Methods of use of fenofibric acid
Aug, 2027

(4 years from now)

Drugs and Companies using FENOFIBRIC ACID ingredient

Market Authorisation Date: 14 August, 2009

Treatment: Adjunctive therapy to diet to patients with hypertriglyceridemia; Adjunctive therapy to diet in patients with hyperlipidemias; Adjunctive therapy to diet in patients with mixed dyslipidemia; Adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels

Dosage: TABLET;ORAL

More Information on Dosage

69. List of Finacea drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700076 LEO PHARMA AS Penetrating pharmaceutical foam
Sep, 2027

(4 years from now)

US10117812 LEO PHARMA AS Foamable composition combining a polar solvent and a hydrophobic carrier
Oct, 2027

(4 years from now)

US9265725 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Dec, 2027

(4 years from now)

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of FINACEA before it's patent expiration?
More Information on Dosage

70. List of Flolipid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300041 TCG FLUENT PHARMA Liquid oral simvastatin compositions
Apr, 2027

(4 years from now)

Drugs and Companies using SIMVASTATIN ingredient

Market Authorisation Date: 21 April, 2016

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

71. List of Forfivo Xl drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7674479 ALMATICA Sustained-release bupropion and bupropion/mecamylamine tablets
Jun, 2027

(4 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient

Market Authorisation Date: 10 November, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of FORFIVO XL before it's patent expiration?
More Information on Dosage

72. List of Galafold drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987263 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US9000011 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US10383864 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US10406143 AMICUS THERAP US Methods for treatment of fabry disease
May, 2027

(4 years from now)

US11241422 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

US9480682 AMICUS THERAP US Methods for treatment of Fabry disease
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023
Orphan Drug Exclusivity (ODE) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's patent expiration?
More Information on Dosage

73. List of Genosyl drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560076 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Apr, 2027

(4 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage

74. List of Genvoya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176220

(Pediatric)

GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Feb, 2027

(4 years from now)

US8981103

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

US7635704

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Apr, 2027

(4 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

75. List of Gilenya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9187405 NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Jun, 2027

(4 years from now)

US9187405

(Pediatric)

NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis
Dec, 2027

(4 years from now)

US10543179 NOVARTIS Dosage regimen of an S1P receptor modulator
Dec, 2027

(4 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Market Authorisation Date: 21 September, 2010

Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment

Dosage: CAPSULE;ORAL

How can I launch a generic of GILENYA before it's patent expiration?
More Information on Dosage

76. List of Gilotrif drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539258

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 12, 2025
M Apr 7, 2025
Pediatric Exclusivity (PED) Oct 15, 2023

Drugs and Companies using AFATINIB DIMALEATE ingredient

Market Authorisation Date: 12 July, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's patent expiration?
More Information on Dosage

77. List of Glyxambi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(4 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations
May, 2027

(4 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's patent expiration?
More Information on Dosage

78. List of Halaven drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46965 EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jan, 2027

(3 years from now)

USRE46965

(Pediatric)

EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jul, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 28, 2023
M Sep 13, 2025
Pediatric Exclusivity (PED) Mar 13, 2026

Drugs and Companies using ERIBULIN MESYLATE ingredient

Market Authorisation Date: 15 November, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of HALAVEN before it's patent expiration?
More Information on Dosage

79. List of Hysingla Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9095614 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9545380 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492390 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9095615 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9486413 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9084816 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9486412 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9775809 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304909 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304908 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HYSINGLA ER before it's patent expiration?
More Information on Dosage

80. List of Ibrance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47739 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
Mar, 2027

(4 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Market Authorisation Date: 03 February, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of IBRANCE before it's patent expiration?
More Information on Dosage

81. List of Iclusig drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114874 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Jan, 2027

(3 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 18, 2023

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 14 December, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ICLUSIG before it's patent expiration?
More Information on Dosage

82. List of Iluvien drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871241 ALIMERA SCIENCES INC Injectable sustained release delivery devices
Aug, 2027

(4 years from now)

Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient

Market Authorisation Date: 26 September, 2014

Treatment: NA

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage

83. List of Imbruvica drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008309 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Nov, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8563563 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Apr, 2027

(4 years from now)

US8476284

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(4 years from now)

US8703780

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(4 years from now)

US8754091

(Pediatric)

PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Jun, 2027

(4 years from now)

US8735403

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(4 years from now)

US8697711

(Pediatric)

PHARMACYCLICS INC Inhibitors of bruton'S tyrosine kinase
Jun, 2027

(4 years from now)

US8497277

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(4 years from now)

US9181257

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(4 years from now)

US8957079

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(4 years from now)

US8952015

(Pediatric)

PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Jun, 2027

(4 years from now)

US7514444

(Pediatric)

PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Jun, 2027

(4 years from now)

US8563563

(Pediatric)

PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Jan 25, 2022
New Patient Population (NPP) Aug 24, 2025
Pediatric Exclusivity (PED) Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 16 February, 2018

Treatment: Treatment of small lymphocytic lymphoma; Treatment of chronic small lymphocytic leukemia; Treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia

Dosage: TABLET;ORAL

How can I launch a generic of IMBRUVICA before it's patent expiration?
More Information on Dosage

84. List of Imcivree drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039435 RHYTHM Melanocortin receptor ligands
Oct, 2027

(4 years from now)

US9458195 RHYTHM Melanocortin receptor ligands
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 25, 2027
New Chemical Entity Exclusivity (NCE) Nov 25, 2025
New Indication (I) Jun 16, 2025

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

85. List of Implanon drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10821277 ORGANON Kit for and method of assembling an applicator for inserting an implant
May, 2027

(4 years from now)

US8722037 ORGANON X-ray visible drug delivery device
Sep, 2027

(4 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

86. List of Incruse Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7488827 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXO GRP ENGLAND Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXO GRP ENGLAND Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Market Authorisation Date: 30 April, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

87. List of Ingrezza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Nov, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

88. List of Injectafer drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478502 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(3 years from now)

US11433091 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(3 years from now)

US8895612 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(3 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Apr 28, 2024
New Patient Population (NPP) Nov 19, 2024

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Method to treat ida in adults with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder weighing at least 40 kg by administering iv ferric carboxymaltose to give at least 0.6 g of iron in 15 minutes or less; Method to treat iron deficiency anemia in adults with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0.6 g of elemental iron in 15 minutes or less; Method to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0.6 g of elemental iron in 15 minutes or less; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g of elemental iron in 15 minutes; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g of elemental iron in less than 15 minutes; Method to treat ida in adults & pediatric patients 1 year & older with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder by administering iv ferric carboxymaltose to give at least 0.7 g of iron in 15 minutes; Method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 46.7 kg by administering iv ferric carboxymaltose to provide at least 0.7 g of elemental iron in < 15 minutes; Method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex, with a substantially non-immunogenic carbohydrate component, in about 15 minutes or less.; Method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; Method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; Method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; Method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; Method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by administering iv at least about 0.6 g of iron as ferric carboxymaltose in about 15 min or less; Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering at least about 0.6 grams of iron as ferric carboxymaltose in about 15 minutes or less

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of INJECTAFER before it's patent expiration?
More Information on Dosage

89. List of Intermezzo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7658945 PURDUE PHARMA Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Apr, 2027

(4 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 23 November, 2011

Treatment: Method for treating insomnia

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of INTERMEZZO before it's patent expiration?
More Information on Dosage

90. List of Invokamet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's patent expiration?
More Information on Dosage

91. List of Invokamet Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's patent expiration?
More Information on Dosage

92. List of Invokana drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

Market Authorisation Date: 29 March, 2013

Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's patent expiration?
More Information on Dosage

93. List of Jakafi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(4 years from now)

US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079912

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Jun, 2027

(4 years from now)

US9814722

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Jun, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Sep 22, 2024
Orphan Drug Exclusivity (ODE) Sep 22, 2028
Pediatric Exclusivity (PED) Nov 24, 2026

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 16 November, 2011

Treatment: For treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; For treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf

Dosage: TABLET;ORAL

How can I launch a generic of JAKAFI before it's patent expiration?
More Information on Dosage

94. List of Janumet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Aug 12, 2022
Pediatric Exclusivity (PED) Jun 4, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 30 March, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JANUMET before it's patent expiration?
More Information on Dosage

95. List of Janumet Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Dec 4, 2023
Pediatric Exclusivity (PED) Jun 4, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 02 February, 2012

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JANUMET XR before it's patent expiration?
More Information on Dosage

96. List of Januvia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Dec 4, 2023
Pediatric Exclusivity (PED) Feb 12, 2023

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 16 October, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JANUVIA before it's patent expiration?
More Information on Dosage

97. List of Jardiance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 18, 2024
M Feb 24, 2025

Drugs and Companies using EMPAGLIFLOZIN ingredient

Market Authorisation Date: 01 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JARDIANCE before it's patent expiration?
More Information on Dosage

98. List of Jatenzo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11331325 CLARUS Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Jan, 2027

(3 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 27, 2022

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 March, 2019

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

99. List of Jentadueto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2012

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET;ORAL

How can I launch a generic of JENTADUETO before it's patent expiration?
More Information on Dosage

100. List of Jentadueto Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(4 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JENTADUETO XR before it's patent expiration?
More Information on Dosage

101. List of Juluca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JULUCA before it's patent expiration?
More Information on Dosage

102. List of Juxtapid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7932268 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Aug, 2027

(4 years from now)

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses

Dosage: CAPSULE;ORAL

More Information on Dosage

103. List of Kalydeco drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Aug, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027
New Patient Population (NPP) Apr 29, 2022

Drugs and Companies using IVACAFTOR ingredient

Market Authorisation Date: 17 March, 2015

Treatment: Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; Method of treating cystic fibrosis; Treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data

Dosage: GRANULE;ORAL

How can I launch a generic of KALYDECO before it's patent expiration?
More Information on Dosage

104. List of Kalydeco drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7495103 VERTEX PHARMS Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324242 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Aug, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using IVACAFTOR ingredient

Market Authorisation Date: 31 January, 2012

Treatment: Method of treating cystic fibrosis; Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide

Dosage: TABLET;ORAL

How can I launch a generic of KALYDECO before it's patent expiration?
More Information on Dosage

105. List of Karbinal Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522191 AYTU Modified release formulations containing drug—ion exchange resin complexes
Jun, 2027

(4 years from now)

Drugs and Companies using CARBINOXAMINE MALEATE ingredient

Market Authorisation Date: 28 March, 2013

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

106. List of Klisyri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001 ALMIRALL Compositions for modulating a kinase cascade and methods of use thereof
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2025

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 14 December, 2020

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage

107. List of Korsuva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10017536 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US8536131 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US7402564 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US7713937 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(4 years from now)

US10793596 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US7727963 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236766 CARA THERAP Uses of synthetic peptide amides
Nov, 2027

(4 years from now)

US8217007 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US8486894 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(4 years from now)

US10138270 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

US9334305 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(4 years from now)

US9359399 CARA THERAP Synthetic peptide amides
Nov, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 23, 2026

Drugs and Companies using DIFELIKEFALIN ACETATE ingredient

NCE-1 date: August, 2025

Market Authorisation Date: 23 August, 2021

Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

108. List of Kybella drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7622130 KYTHERA BIOPHARMS Methods and compositions for the non-surgical removal of fat
Dec, 2027

(4 years from now)

US7754230 KYTHERA BIOPHARMS Methods and related compositions for reduction of fat
Dec, 2027

(4 years from now)

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Market Authorisation Date: 29 April, 2015

Treatment: Method for reduction of submental fat

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of KYBELLA before it's patent expiration?
More Information on Dosage

109. List of Kynamro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511131 KASTLE THERAPS LLC Antisense modulation of apolipoprotein B expression
Jan, 2027

(3 years from now)

Drugs and Companies using MIPOMERSEN SODIUM ingredient

Market Authorisation Date: 29 January, 2013

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

110. List of Kyprolis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7737112 ONYX THERAP Composition for enzyme inhibition
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 20, 2023

Drugs and Companies using CARFILZOMIB ingredient

Market Authorisation Date: 20 July, 2012

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KYPROLIS before it's patent expiration?
More Information on Dosage

111. List of Lastacaft drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617695 ALLERGAN Ophthalmic compositions containing alcaftadine
Mar, 2027

(4 years from now)

US8664215 ALLERGAN Ocular allergy treatments with alcaftadine
Dec, 2027

(4 years from now)

Drugs and Companies using ALCAFTADINE ingredient

Market Authorisation Date: 28 July, 2010

Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LASTACAFT before it's patent expiration?
More Information on Dosage

112. List of Lenvima drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006256 EISAI INC Antitumor agent for thyroid cancer
Jul, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2025
New Indication (I) Aug 10, 2024
M Dec 19, 2024

Drugs and Companies using LENVATINIB MESYLATE ingredient

Market Authorisation Date: 13 February, 2015

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer

Dosage: CAPSULE;ORAL

How can I launch a generic of LENVIMA before it's patent expiration?
More Information on Dosage

113. List of Leqvio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8809292 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222222 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

114. List of Letairis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377933 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(4 years from now)

US9474752 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(4 years from now)

Drugs and Companies using AMBRISENTAN ingredient

Market Authorisation Date: 15 June, 2007

Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil

Dosage: TABLET;ORAL

How can I launch a generic of LETAIRIS before it's patent expiration?
More Information on Dosage

115. List of Levitra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8273876 BAYER HLTHCARE Medicaments containing vardenafil hydrochloride trihydrate
Jul, 2027

(4 years from now)

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Market Authorisation Date: 19 August, 2003

Treatment: Treatement of erectiile dysfunction by administering a film-coated tablet

Dosage: TABLET;ORAL

How can I launch a generic of LEVITRA before it's patent expiration?
More Information on Dosage

116. List of Lexiscan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(4 years from now)

Drugs and Companies using REGADENOSON ingredient

Market Authorisation Date: 10 April, 2008

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEXISCAN before it's patent expiration?
More Information on Dosage

117. List of Lumigan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851504 ALLERGAN Enhanced bimatoprost ophthalmic solution
Jun, 2027

(4 years from now)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 31 August, 2010

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIGAN before it's patent expiration?
More Information on Dosage

118. List of Lynparza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071579 ASTRAZENECA DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(4 years from now)

US8143241 ASTRAZENECA DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 8, 2027
New Indication (I) Mar 11, 2025

Drugs and Companies using OLAPARIB ingredient

Market Authorisation Date: 17 August, 2017

Treatment: Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; Treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; Maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy; Treatment of brca mutated ovarian cancer using parp inhibitor

Dosage: TABLET;ORAL

How can I launch a generic of LYNPARZA before it's patent expiration?
More Information on Dosage

119. List of Lyrica Cr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022447

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(4 years from now)

US8945620

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(4 years from now)

US9144559

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(4 years from now)

Drugs and Companies using PREGABALIN ingredient

Market Authorisation Date: 11 October, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of LYRICA CR before it's patent expiration?
More Information on Dosage

120. List of Macrilen drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 20, 2024
New Chemical Entity Exclusivity (NCE) Dec 20, 2022

Drugs and Companies using MACIMORELIN ACETATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 20 December, 2017

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

121. List of Mekinist drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2024
M Oct 6, 2022
New Indication (I) Jun 22, 2025

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

122. List of Moxatag drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8299052 PRAGMA Pharmaceutical compositions and methods for improved bacterial eradication
May, 2027

(4 years from now)

Drugs and Companies using AMOXICILLIN ingredient

Market Authorisation Date: 23 January, 2008

Treatment: Use of once-a-day amoxicillin product to treat tonsillitis and/or pharyngitis secondary to streptococcus pyogenes

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

123. List of Neupro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246979 UCB INC Transdermal delivery system for the administration of rotigotine
Sep, 2027

(4 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Market Authorisation Date: 09 May, 2007

Treatment: Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; Treatment of restless legs syndrome by application of claimed transdermal delivery system

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic